Skip to main content
Fig. 1 | BMC Immunology

Fig. 1

From: JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation

Fig. 1

TOFA improved clinical manifestations in BWF1 mice. Urine and blood were evaluated for (a) proteinuria and (b) anti-dsDNA antibody titres in BWF1. Spleen size (c, left) and weight in BWF1 (c, right). Boxplot shows median and interquartile ranges from minimum to maximum [TOFA (BWF1: n = 13); TOFA + DEXA (BWF1: n = 15); DEXA (BWF1: n = 8); and control (BWF1: n = 13)]. **p < 0.01; ***p < 0.001 and ****p < 0.0001 (vs. control mice). BWF1: NZB/NZW F1 mice; DEXA: dexamethasone; TOFA: tofacitinib

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us